The U.S. Food and Drug Administration has launched the Neuroscience and Innovation Nexus program, NAIN, to coordinate scientific and regulatory work on drugs, biologics, and medical devices for brain and nervous system diseases. Its first initiative, the Alzheimer’s Prevention Accelerator, will explore clinical trial populations, stage-appropriate endpoints, and evidence of preventing cognitive decline for Alzheimer’s prevention and early-intervention drugs, while involving patients, caregivers, researchers, industry, and federal agencies.
Source:FDA · Read the Original
Leave a Reply